Antihistone and Other Autoantibodies in β-Thalassemia major Patients Receiving Iron Chelators

Publisher： Karger

E-ISSN： 1421-9662|109|1|35-39

ISSN： 0001-5792

Source： Acta Haematologica, Vol.109, Iss.1, 2002-12, pp. : 35-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study

By Scalone Luciana   Mantovani Lorenzo G.   Krol Marieke   Rofail Diana   Ravera Simona   Grazia Bisconte Maria   Borgna-Pignatti Caterina   Borsellino Zelia   Cianciulli Paolo   Gallisai Domenico   Prossomariti Luciano   Stefàno Ippazio   Cappellini Maria D.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1905-1917

Informa Healthcare

Access to resources Recommend Favorite

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β‐thalassemia major: A prospective, single center, open‐label study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1592-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thromboembolism in β-Thalassemia Major

By  

Acta Haematologica, Vol. 100, Iss. 3, 1998-12 ,pp. : 166-166

Karger

Access to resources Recommend Favorite

Plasma Homocysteine Is Not Involved in the Thrombotic Risk of β-Thalassemia major Patients

By  

Acta Haematologica, Vol. 104, Iss. 2-3, 2001-01 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite